Hypothesis
In aged skeletal muscle, the metabolic benefits of L-carnitine supplementation depend on the cellular AMPK activity state: high AMPK activation inhibits carnitine uptake and limits fatty acid oxidation, whereas reduced AMPK signaling permits carnitine to restore shuttle flux and improve mitochondrial function.
Mechanistic rationale
Research shows that L-carnitine raises muscle carnitine pools and boosts fat oxidation by supplying substrate for the carnitine acetyltransferase (CAT) and carnitine palmitoyltransferase (CPT) enzymes, without invoking classic hormetic pathways like NRF2/AMPK[1,2]. Conversely, AMPK activators blunt L-carnitine transport in cultured myotubes[3] and lifespan extensions observed in C. elegans via SKN-1/DAF-16 do not translate to mammals, where carnitine alone fails to improve strength or body composition[4,5].
We propose that AMPK phosphorylates the organic cation transporter OCTN2 (the primary carnitine importer) or associated regulatory proteins, decreasing its Vmax or increasing its Km for carnitine. This post‑translational modification creates a substrate‑limiting bottleneck that cannot be overcome by merely increasing extracellular carnitine. When AMPK activity is low, OCTN2 operates at higher affinity, allowing supplemented carnitine to raise intracellular concentrations, thereb





























